Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Net Cash Flow: 2016-2024

Historic Net Cash Flow for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to $6.3 million.

  • Solid Biosciences' Net Cash Flow fell 36.50% to $15.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.3 million, marking a year-over-year increase of 107.55%. This contributed to the annual value of $6.3 million for FY2024, which is 107.79% up from last year.
  • As of FY2024, Solid Biosciences' Net Cash Flow stood at $6.3 million, which was up 107.79% from -$81.4 million recorded in FY2023.
  • Solid Biosciences' 5-year Net Cash Flow high stood at $78.7 million for FY2020, and its period low was -$81.4 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was $6.3 million (2024), whereas its average is -$13.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 862.38% in 2020, then slumped by 325.96% in 2023.
  • Yearly analysis of 5 years shows Solid Biosciences' Net Cash Flow stood at $78.7 million in 2020, then crashed by 143.03% to -$33.9 million in 2021, then soared by 206.34% to $36.0 million in 2022, then crashed by 325.96% to -$81.4 million in 2023, then spiked by 107.79% to $6.3 million in 2024.